Home › Research › Getting a diagnosis
Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study
Imfeld P, Bodmer M, Jick SS, Meier CR.. Journal of the American Geriatrics Society, 2012-03-28
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objectives To explore the risk of developing Alzheimer's disease (AD) in individuals with diabetes mellitus treated with metformin or other antidiabetic drugs. Design Case-control study. Setting The United Kingdom-based General Practice Research Database (GPRD), a well-established primary care database. Participants Seven thousand eighty-six individuals aged 65 and older with an incident diagnosis of AD identified between 1998 and 2008 and the same number of matched controls without dementia. Matching criteria were age, sex, general practice, calendar time, and years of history in the database. Measurements Comparison of previous use of metformin or other antidiabetic drugs between cases and controls and calculation of corresponding odds ratios (ORs) with 95% confidence intervals (CIs), using conditional logistic regression. Risk estimates were stratified according to duration of use and adjusted for potential confounders. Results As compared with nonusers, long-term users of 60 or more metformin prescriptions were at greater risk of developing AD (adjusted OR (AOR) = 1.71, 95% CI = 1.12-2.60), but there was no consistent trend with increasing number of prescriptions. Long-term use of other antidiabetic drugs such as sulfonylureas (AOR = 1.01, 95% CI = 0.72-1.42), thiazolidinediones (AOR = 0.87, 95% CI = 0.31-2.40), or insulin (AOR = 1.01, 95% CI = 0.58-1.73) was not related to an altered risk of developing AD. Conclusion Long-term use of sulfonylureas, thiazolidinediones, or insulin was not associated with an altered risk of developing AD. There was a suggestion of a slightly higher risk of AD in long-term users of metformin.
What this study adds
Evidence grade: Moderate
This is a case-control study. In this case-control study, long-term use of metformin was associated with a slightly higher risk of Alzheimer's disease, but there was no consistent trend with more prescriptions. Reported effect size: AOR = 1.01; AOR = 0.87.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Imfeld, P., Bodmer, M., Jick, S. S., & Meier, C. R. (2012). Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2012.03916.x
Vancouver
Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. Journal of the American Geriatrics Society. 2012. doi:10.1111/j.1532-5415.2012.03916.x. PMID: 22458300.
BibTeX
@article{imfeld2012-22458300,
author = {Imfeld, P. and Bodmer, M. and Jick, S. S. and Meier, C. R.},
title = {{Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study}},
journal = {Journal of the American Geriatrics Society},
year = {2012},
doi = {10.1111/j.1532-5415.2012.03916.x},
pmid = {22458300},
url = {https://doi.org/10.1111/j.1532-5415.2012.03916.x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results As compared with nonusers, long-term users of 60 or more metformin prescriptions were at greater risk of developing AD (adjusted OR (AOR) = 1.71, 95% CI = 1.12-2.60), but there was no consistent trend with increasing number of prescriptions.
- Conclusion Long-term use of sulfonylureas, thiazolidinediones, or insulin was not associated with an altered risk of developing AD.
- There was a suggestion of a slightly higher risk of AD in long-term users of metformin.
Why it matters
In this case-control study, long-term use of metformin was associated with a slightly higher risk of Alzheimer's disease, but there was no consistent trend with more prescriptions. Long-term use of sulfonylureas, thiazolidinediones, or insulin was not associated with an altered risk.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Study designcase-control study
- Effect sizeAOR = 1.01; AOR = 0.87
- Evidence strengthModerate
How this study scored 60/100
Published in a peer-reviewed journal, and it is a case-control study. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the American Geriatrics Society) |
| Journal's citation record | 3 / 4 | Journal of the American Geriatrics Society: journal h-index 344 (OpenAlex, 2026-10-29) |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 388 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 24.2 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 4 / 6 | Cited 10.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 14 other studies in this library |
| Still being cited | 3 / 4 | Cited 66 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Christoph Rudolf Meier: h-index 51 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Boston University: institution h-index 1,456 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 22458300) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
14 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.